Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Golubic R., Hussein Ismail M., Josipovic M., Kennet J., Galderisi A., Evans ML.